PCa

Related by string. PCAS . PCAD . PCA . PCAs * * PCA Blakely . PCA Rx . Guava PCA . Guava PCA systems . LifeCare PCA . PCA Plainview . controlled analgesia PCA . TSX PCA . PCA stadium . PCA Stadium . PCA Developer . PCA CN . prostate cancer PCa . Arbitration PCA . PCA SKIN . PCA Directive . Colonial PCA . PCA Ciclos Uno . PCA Professional Cricketers *

Related by context. All words. (Click for frequent words.) 78 prostate cancer CaP 75 prostate cancer PCa 75 urothelial carcinoma 74 biochemical recurrence 73 CIN2 + 72 lymph node metastasis 72 HGPIN 72 prostate carcinoma 72 advanced adenoma 72 CaP 72 colorectal carcinoma 71 neoplasia 71 adenoma 71 epithelial ovarian cancer 71 lymph node metastases 71 radical prostatectomy RP 70 breast carcinoma 70 advanced adenomas 70 renal tumors 70 breast carcinomas 70 micrometastases 70 pT3 70 pT2 70 neoplasm 70 specific antigen PSA 70 thyroglobulin 69 ADPKD 69 lobular carcinoma 69 mucinous 69 pancreatic adenocarcinoma 69 serum PSA 69 advanced neoplasia 69 HNSCC 69 atypical hyperplasia 69 distant metastasis 69 prostate adenocarcinoma 69 histological subtype 69 GISTs 69 heterozygotes 69 pelvic lymphadenectomy 69 adenocarcinomas 68 clinically localized prostate 68 mRNA expression 68 KRAS mutation 68 cervical carcinoma 68 neoplasias 68 ovarian carcinoma 68 HER2 expression 68 seminomas 68 NMIBC 68 colorectal neoplasms 68 lymphadenectomy 68 colorectal adenoma 68 EBRT 68 univariate analysis 68 BRCA2 mutation carriers 68 nodal metastasis 68 tumor recurrence 68 microalbuminuria 68 EUS FNA 68 paragangliomas 68 neoplasms 68 metastatic prostate cancer 68 MGUS 67 T2DM 67 node metastases 67 immunohistochemical 67 distant metastases 67 urothelial cancer 67 malignant nodules 67 histologically 67 pheochromocytoma 67 serum testosterone 67 renal artery stenosis 67 ASCUS 67 immunostaining 67 TT genotype 67 malignant lesions 67 epithelial tumors 67 serous ovarian cancer 67 preoperative PSA 67 PSADT 67 invasive carcinomas 67 endometrial carcinoma 67 ABCB1 67 hepatocellular carcinomas 67 TNF α 67 thyroid carcinoma 67 thyroid nodules 67 cutaneous melanoma 67 esophageal carcinoma 67 rs# [004] 67 cytoreductive nephrectomy 67 cystectomy 66 invasive carcinoma 66 gastric adenocarcinoma 66 nonmetastatic 66 intestinal metaplasia 66 bladder carcinoma 66 immunohistochemical staining 66 differentiated thyroid 66 angiographically 66 K ras mutations 66 carotid stenosis 66 serum prostate 66 rs# [002] 66 carcinomas 66 seminal vesicle invasion 66 urine cytology 66 histologic subtype 66 Clusterin 66 estrogen receptor ER 66 colorectal tumors 66 micrometastasis 66 microsatellite instability 66 leiomyomas 66 malignant pleural mesothelioma 66 MetS 66 CIN3 66 extracapsular extension 66 TIMP 66 colorectal cancer CRC 66 neoadjuvant chemotherapy 66 lymphocytosis 66 nodal metastases 66 grade cervical intraepithelial 66 germline mutations 66 basal cell carcinoma BCC 66 adenomatous polyps 66 HLA DR 66 Sjögren syndrome 66 HER2 amplification 66 Subgroup analysis 66 carcinoma 66 biochemical relapse 66 androgen deprivation 66 promoter methylation 66 liver metastases 66 nephrogenic 66 HER2 overexpression 65 adjuvant radiotherapy 65 ERBB2 65 esophageal squamous cell carcinoma 65 prostate tumor 65 cytokeratin 65 squamous intraepithelial lesions 65 subclinical 65 neoplastic 65 BRAF mutation 65 operable breast cancer 65 locoregional recurrence 65 immunohistochemical analysis 65 GSTP1 65 atypia 65 papillary thyroid carcinoma 65 transurethral resection 65 Lymph node 65 malignant lymphoma 65 SLNB 65 gene amplification 65 prognostic factor 65 #.#ng/ml 65 tPSA 65 hepatoma 65 prostate cancers 65 LV dysfunction 65 intact parathyroid hormone 65 prognostic significance 65 nonalcoholic steatohepatitis NASH 65 thymoma 65 gastric carcinoma 65 adrenalectomy 65 T1a 65 FLT3 65 rs# [001] 65 PSA nadir 65 invasive ductal 65 cTnI 65 CC genotype 65 atherosclerotic lesions 65 cTnT 65 liver metastasis 65 completely resected 65 carcinoembryonic antigen 65 diabetes mellitus DM 65 histologic 65 B7 H3 65 castrate resistant 65 metastases 65 prognostic indicator 65 seminoma 65 homozygotes 65 metastatic lymph nodes 65 SNP rs# [001] 65 contralateral breast 65 prostatic 65 lymphovascular invasion 65 FDG uptake 65 MSH2 65 androgen independent 65 pCR 65 chemosensitivity 65 malignancy 65 elevated CRP 65 prognostic variables 65 prostate cancer CRPC 65 transitional cell carcinoma 65 lymph node involvement 65 pg ml 65 BRAF V#E mutation 65 histologically confirmed 65 rs# [003] 65 renal cell carcinomas 65 SNP rs# [002] 65 ErbB2 positive 64 metastatic renal cell carcinoma 64 alkaline phosphatase ALP 64 colorectal liver metastases 64 MLH1 64 polyp recurrence 64 Hurthle cell 64 axillary lymph nodes 64 hepatocellular carcinoma HCC 64 D dimer 64 TP# mutations 64 radical cystectomy 64 neoadjuvant 64 antibody titer 64 testicular germ cell 64 cervical intraepithelial neoplasia 64 TMPRSS2 ERG 64 Immunohistochemical analysis 64 obstructive coronary artery 64 rheumatoid factor 64 hyperplastic 64 situ LCIS 64 bladder cancers 64 troponin T 64 SPINK1 64 locoregional 64 subclinical atherosclerosis 64 T#I [002] 64 pulmonary metastases 64 pathologic 64 EGFR mutation 64 pre malignant lesions 64 endometrial cancers 64 premalignant lesions 64 TRUS 64 multivariate analyzes 64 KRAS mutations 64 metastatic lesions 64 metachronous 64 coronary stenosis 64 #F FDG PET 64 F FDG PET 64 colorectal neoplasia 64 Leydig cell 64 MTHFR 64 EGFR mutations 64 malignant neoplasm 64 prostatic adenocarcinoma 64 monocyte chemoattractant protein 64 precursor lesions 64 HBsAg 64 Immunohistochemical staining 64 chlamydial infection 64 PTPN# 64 radical nephrectomy 64 ERCC1 64 breast lesions 64 Inhibin B 64 malignant prostate 64 neoadjuvant therapy 64 APOE e4 64 T2D 64 liver histology 64 metastatic malignant 64 hydronephrosis 64 hamartomas 64 castrate resistant prostate cancer 64 μmol L 64 macroalbuminuria 64 preoperative chemotherapy 64 autoantibodies 64 ZNF# 64 varicocele 64 variant allele 64 BRAF V#E 64 MSMB 64 endometrioid 64 cisplatin resistant 64 ovarian tumors 63 HER2 + 63 adenocarcinoma 63 urothelial 63 peritoneal carcinomatosis 63 Papillary 63 recurrent VTE 63 NGAL 63 androgen receptor AR 63 IL 1ß 63 microvessel density 63 urothelial bladder cancer 63 underwent radical prostatectomy 63 hepatocellular carcinoma 63 perioperative complications 63 FDG PET 63 survivin 63 mesotheliomas 63 mRCC 63 thromboembolic events 63 thyrotropin 63 lymphoproliferative disorders 63 somatic mutations 63 Ki# 63 clusterin 63 multivariate Cox 63 homozygosity 63 COL#A# 63 prognostic marker 63 chemoresistant 63 prognostic biomarker 63 metastatic tumors 63 univariate 63 p = #.# [003] 63 TOP2A 63 periprocedural 63 metaplasia 63 histopathologic 63 univariate analyzes 63 stage IIIB 63 P = .# 63 radical prostatectomy 63 alanine aminotransferase ALT 63 prostate biopsy 63 Radical prostatectomy 63 radiotherapy RT 63 isoenzyme 63 bladder tumors 63 tumorigenicity 63 sarcomatoid 63 mammographic density 63 pleomorphic 63 FDG PET imaging 63 antigen PSA 63 resectable 63 SUVmax 63 lactate dehydrogenase 63 myeloproliferative diseases 63 squamous cell carcinoma SCC 63 BRCA mutations 63 RASSF1A 63 pg mL 63 sporadic ALS 63 FGFR1 63 bone metastasis 63 tumor necrosis 63 squamous 63 NSCLC tumors 63 subclinical hyperthyroidism 63 logistic regression analysis 63 immunoreactivity 63 activating mutation 63 metastatic malignant melanoma 63 estrogen receptor negative 63 TMPRSS2 ERG fusion 63 intima media thickness 63 PCA3 scores 63 CIN3 + 63 progesterone receptor negative 63 hematopoietic cancers 63 tumors 63 lung metastases 63 adenomas 63 ischemic lesions 63 Adenomas 63 confidence interval #.#-#.# 63 IGFBP 63 CYP#D# 63 refractory prostate cancer 63 cholangiocarcinoma 63 osteosarcomas 63 clinicopathological features 63 KRAS oncogene 63 undergoing radical prostatectomy 63 orchiectomy 63 LNCaP cells 63 mutated KRAS 63 proto oncogene 63 superficial bladder cancer 63 ErbB2 63 lobular carcinomas 63 contralateral breast cancer 63 cervical lymph nodes 63 CIN2 63 carcinoid tumor 63 BRCA1 mutation carriers 63 bilateral oophorectomy 63 CP CPPS 63 Kaplan Meier analysis 63 Her2/neu 63 FGFR2 63 IgA deficiency 63 PTEN mutations 63 gene polymorphisms 63 malignant ovarian 63 IL#B 63 occult metastases 63 pituitary adenomas 63 neoplastic lesions 63 colorectal polyp 63 BRCA2 carriers 63 pancreatic carcinoma 63 ductal 63 TNFalpha 63 pheochromocytomas 63 subclinical hypothyroidism 63 SSc 63 serum TSH 63 cervical lesions 62 cyclin E 62 differentially expressed genes 62 acute aortic dissection 62 total thyroidectomy 62 adrenal masses 62 Prostate Specific Antigen 62 intravesical therapy 62 hypermethylated 62 HER2 negative 62 tHcy 62 nephrectomy 62 BRAF mutations 62 adenomatous 62 chemoradiotherapy 62 FDG-PET/CT 62 ERalpha 62 situ CIS 62 uPAR 62 abnormal cytology 62 invasive lobular 62 morphologic 62 LRP5 62 poorer prognosis 62 oropharyngeal cancer 62 breast cancer subtypes 62 transrectal ultrasound guided 62 miRNA expression 62 leukemia AML 62 TACE 62 K#R [002] 62 HLA DR4 62 platelet reactivity 62 ductal adenocarcinoma 62 ^ sup #m 62 HNPCC 62 transgene expression 62 hypogonadal 62 syngeneic 62 p# biomarker 62 bone scintigraphy 62 resected 62 clinicopathological 62 immunocompetent 62 NNRTI resistance 62 colorectal adenocarcinoma 62 genetic polymorphisms 62 prognostically 62 UGT#A# 62 intratumoral 62 metastatic RCC 62 albuminuria 62 rebleeding 62 TCF#L# 62 atrophic gastritis 62 carcinoid tumors 62 Endometrial 62 colorectal adenomas 62 LRP6 62 hereditary hemochromatosis 62 lung adenocarcinoma 62 RRM1 62 cerebral infarction 62 BRCA mutation carriers 62 IFN γ 62 cytologic 62 HBeAg negative 62 serum urate levels 62 tumor histology 62 perfusion abnormalities 62 HER2 positive metastatic breast 62 HER2 positive cancers 62 T1c 62 T2 lesions 62 Her2 62 ccRCC 62 epithelial ovarian 62 thromboembolism 62 % CI #.#-#.# [003] 62 PARP inhibition 62 cardiac troponin T 62 histopathological 62 STRIDE PD 62 coronary artery stenosis 62 sarcosine 62 ultrasonographic 62 hTERT 62 gallstone disease 62 axillary node 62 MALT lymphoma 62 papillary 62 IGF 1R 62 HER2 receptor 62 hyperparathyroidism 62 Hashimoto thyroiditis 62 IFN α 62 c MYC 62 multivariable analysis 62 EGFR tyrosine kinase inhibitors 62 Metastatic 62 hematologic toxicity 62 allelic variants 62 HIV HCV coinfected 62 leiomyoma 62 histologic subtypes 62 urolithiasis 62 follicular thyroid cancer 62 antigen PSA levels 62 ductal cancer 62 CLL cells 62 5alpha reductase 62 steroidogenesis 62 CD#c 62 hepatic fibrosis 62 VKORC1 62 castration resistant prostate cancer 62 colorectal carcinomas 62 PIK3CA 62 IDH1 mutation 62 MAPK pathway 62 WT1 62 lung metastasis 62 GSTM1 62 testicular cancers 62 nasopharyngeal carcinoma 62 adenoma recurrence 62 Prostate specific antigen 62 gene polymorphism 62 histologies 62 prostate cancer AIPC 62 severe neutropenia 62 anaplastic 62 colorectal polyps 62 recurrent glioblastoma multiforme 62 mutated K ras 62 PC3 cells 62 intestinal polyps 62 carotid plaques 62 GIST tumors 62 noncardiac 62 proximal colon 62 H#K#me# 62 hENT1 62 hormone receptor negative 62 serum concentrations 62 gadolinium enhanced 62 Fas ligand 62 HepG2 cells 62 metastatic disease 62 uveal melanoma 62 #beta 62 IFN beta 62 metastatic prostate 62 HER2 gene 62 paraganglioma 62 ALK mutations 61 HBeAg positive 61 allele frequencies 61 liver resection 61 CD#b 61 D Dimer 61 papillary carcinoma 61 POAG 61 periprocedural MI 61 choroidal neovascularization 61 carcinoids 61 PCNSL 61 myeloproliferative disorder 61 varicoceles 61 lactate dehydrogenase LDH 61 papillary renal cell carcinoma 61 serum creatinine levels 61 nonfatal MI 61 haematopoietic 61 immunoblotting 61 androgen deficiency 61 hepatic metastases 61 HAAH 61 hematuria 61 chronic prostatitis 61 #q#.# [001] 61 intrahepatic 61 E selectin 61 antitumor effect 61 Subgroup analyzes 61 ventricular myocardium 61 dysglycemia 61 grade squamous intraepithelial 61 microdeletions 61 virologic response 61 nonmelanoma skin cancers 61 CsA 61 recurrent NSCLC 61 mononuclear 61 recurrent prostate cancer 61 effector function 61 methylated DNA 61 breast cancer metastasis 61 prospectively defined 61 IV NSCLC 61 transferrin saturation 61 seropositivity 61 histologically proven 61 anti JCV antibodies 61 prostatic hyperplasia 61 colon carcinoma 61 chemoresistance 61 biliary tract cancer 61 gefitinib Iressa 61 renal cysts 61 logistic regression analyzes 61 Histological 61 ERK1 2 61 vimentin 61 Carcinoma 61 scintigraphic 61 malignant polyps 61 endometrial hyperplasia 61 pulmonary nodules 61 cytoreductive surgery 61 onset diabetes mellitus 61 PITX2 61 endosonography 61 IGFBP 3 61 prognostic markers 61 FGFR3 61 ductal breast cancer 61 surgically resected 61 germline mutation 61 serum ALT 61 tumor subtypes 61 penetrance 61 undetectable PSA 61 seronegative 61 LTBI 61 intraepithelial neoplasia 61 cutaneous squamous cell carcinoma 61 schwannomas 61 definite stent thrombosis 61 Adjuvant chemotherapy 61 polyposis 61 metastatic gastric 61 plasma kallikrein 61 TIMP 1 61 antiangiogenic therapy 61 KRAS status 61 cancer mCRC 61 EGFRvIII 61 neuroendocrine cancers 61 Leukemias 61 metastatic cancer 61 nephron sparing surgery 61 cyclooxygenase 2 61 posttransplant 61 adjuvant therapies 61 CDKN2A 61 adiponectin concentrations 61 interleukin IL -# 61 breast tumors 61 CagA 61 confidence intervals CIs 61 CYP#A# [002] 61 F FDG uptake 61 soluble receptor 61 flutamide 61 CYP# [002] 61 androgen suppression 61 nanomolar 61 graft dysfunction 61 monoclonal gammopathy 61 Troponin T 61 Asymptomatic 61 obstructive coronary 61 chromosomal rearrangement 61 PDGFR 61 % CI #.#-#.# [007] 61 cirrhotic 61 inducible nitric oxide synthase 61 mitochondrial toxicity 61 APOL1 61 natriuretic peptide 61 adjuvant chemotherapy 61 duplex ultrasonography 61 allele frequency 61 isoprostane 61 LVNC 61 normal karyotype 61 microscopic hematuria 61 cerebral microbleeds 61 liver fibrosis 61 Adenocarcinoma 61 lymph node dissection 61 COX2 61 primary aldosteronism 61 bioavailable testosterone 61 AGTR1 61 prostate specific 61 sentinel lymph node biopsy 61 osteopenic 61 elevated LDH 61 xenografts 61 cell carcinomas 61 aminotransferase 61 BRCA1 mutations 61 iNOS 61 qRT PCR 61 premalignant 61 ovarian malignancy 61 papillary RCC 61 miR #a [001] 61 grade gliomas 61 relapsed MM 61 coronary artery calcium 61 external beam radiotherapy 61 perioperatively 61 Histologic 61 activating mutations 61 prospectively randomized 61 hippocampal atrophy 61 xenograft tumors 61 neoplastic cells 61 ductal lobular 61 serrated polyps 61 p = .# [002] 61 Akt activation 61 MYCN amplification 61 abdominal adiposity 61 vertebral fracture 61 PCA3 gene 61 sonographically 61 paroxysmal AF 61 etiologic 61 ductal carcinomas 61 CSF biomarkers 61 specific antigen 61 HER-2/neu 61 BRCA mutation 61 urothelium 61 endoscopic ultrasonography 61 hyperoxaluria 61 precancer 61 castration resistant 61 CD# expression [002] 61 Anaplastic 61 skeletal metastases 61 Nilotinib 61 Epidermal Growth Factor Receptor 61 Cystectomy 61 undetectable HBV DNA 61 Alkaline Phosphatase 61 IgG antibodies 61 GH deficiency 61 GSTT1 61 thiopurine 61 vestibular schwannomas 61 heterozygous 61 lymphoid cells 61 Multivariate analysis 61 mutational status 61 hepatectomy 61 multivariate logistic regression 61 IV bisphosphonates 61 HCV genotype 61 DFMO 61 LHRH receptor positive 61 mg kg dose 61 del 5q 61 μg liter 61 nonischemic 61 Lp PLA 2 61 lung nodules 61 variant alleles 61 HLA B# 61 serum IGF 61 PAOD 61 thyrotoxicosis 61 malignant transformation 61 autoantibody 61 lupus anticoagulant 61 PNET 61 cystatin C 61 apolipoproteins 61 colonic polyps 61 μg ml 61 eIF 4E 61 IFN gamma 61 polycythemia vera PV 61 idiopathic myelofibrosis 61 BCG refractory 60 ABL1 60 colorectal tumor 60 neovascular 60 serum testosterone levels 60 biopsy Gleason 60 sentinel nodes 60 ventricular dysfunction 60 IgA antibodies 60 trans retinoic acid 60 intestinal permeability 60 ovarian cancers 60 renal carcinoma 60 Doxil ® 60 spiral computed tomography 60 osteoblast 60 CDK4 60 liver transplant recipients 60 AST ALT 60 malignancies 60 activin 60 receptor tyrosine kinase inhibitor 60 TRAIL R1 60 clinicopathologic 60 IGF IR 60 K ras 60 coronary calcification 60 Ischemic 60 KLF4 60 thromboembolic complications 60 K#N 60 alanine aminotransferase 60 prostate cancer HRPC 60 HBeAg 60 H pylori 60 aromatase 60 nondiabetic patients 60 susceptibility loci 60 GRP# 60 aneuploidies 60 HSCT 60 mTOR inhibitors 60 proteinuria 60 HIV RNA 60 pancreatectomy 60 postoperative complication 60 axillary lymph node 60 cAMP signaling 60 GnRH agonists 60 cardiac troponin 60 adjuvant radiation 60 myocardial ischemia 60 collagenous colitis 60 genotypic resistance 60 JAK2 mutation 60 caveolin 1 60 nonsmall cell lung cancer 60 NAT2 60 proteolytic cleavage 60 KRAS wild 60 MnSOD 60 β amyloid 60 troponins 60 cell adhesion molecule 60 elevated ALT 60 transabdominal 60 postoperative morbidity 60 lymphocyte counts 60 EGFR receptor 60 stage IIIA 60 prostate epithelial cells 60 C#BL 6 mice 60 mammary tumors 60 paricalcitol 60 presymptomatic 60 interleukin IL 60 LSIL 60 prognostic indicators 60 plasma renin activity 60 clinically insignificant 60 carotid IMT 60 NKG2D 60 mediastinoscopy 60 TOP2A gene 60 c KIT 60 tumor xenograft models 60 R0 resection 60 varices 60 kidney allograft 60 HDACi 60 hyperplasia 60 microbleeds 60 serum selenium 60 renal cell carcinoma 60 trastuzumab Herceptin ® 60 5FU 60 plasma lipid 60 adjuvant therapy 60 cancerous enlargement 60 tumor biopsies 60 NAFLD 60 antiproliferative effects 60 LHRH agonists 60 systolic hypertension 60 mycosis fungoides 60 needle aspiration 60 NMP# 60 sentinel node 60 System IPSS 60 meningiomas 60 highest tertile 60 fibroadenomas 60 thyroid stimulating hormone 60 hypogonadotropic hypogonadism 60 lymphocytic 60 APTIMA HPV 60 molecular subtypes 60 noncarriers 60 variant rs# 60 metastatic colorectal 60 parathyroid 60 malignant phenotype 60 HG PIN 60 #F FDG PET CT 60 Neoadjuvant 60 GNAQ 60 CTEPH 60 CHEK2 60 cellularity 60 TLR3 60 lipid abnormalities 60 neoplasia PIN 60 underwent surgical resection 60 histopathologic examination 60 perineural invasion 60 hypoperfusion 60 TEAEs 60 astrocytomas 60 glomerular filtration 60 serum antibodies 60 Rap1 60 HRCT 60 tyrosine phosphorylation 60 smoldering myeloma 60 tumoral 60 tryptase 60 missense mutations 60 mCRC patients 60 BRCA1 BRCA2 60 peritoneal cancer 60 acute GvHD 60 Lp PLA2 60 hip BMD 60 invasive lobular carcinoma 60 urine dipstick 60 cytological 60 bronchogenic carcinoma 60 testicular tumors 60 lung carcinomas 60 PsA 60 Haptoglobin 60 PTEN gene 60 MMP# 60 hepatic resection 60 Squamous 60 axillary dissection 60 TNFα 60 soft tissue sarcomas 60 splice variants 60 Prostatic 60 antibody titers 60 esophagogastric junction 60 postoperative delirium 60 prognostic factors 60 NSCLC 60 TRUS biopsy 60 Prostate Specific Antigen PSA 60 gastric cancers 60 APOE ε4 60 mL/min/#.# m 2 60 mosaicism 60 anti apoptotic proteins 60 p# Shc 60 medullary thyroid cancer 60 β blockers 60 virologic failure 60 serum calcium 60 #p# [001] 60 euthyroid 60 prostate specific antigen 60 Neutrophil

Back to home page